Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents)

Volume 6 Issue 4
ISSN: 1871-5257
eISSN: 1875-6182


   All Titles

  Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
  pp.253-257 (5) Authors: P. J. Blankestijn, H. Rupp

Rationale. The goal of antihypertensive treatment is to reduce risk of cardiovascular morbidity and mortality. Apart from blood pressure lowering per se, also reducing the activities of the renin-angiotensin system and sympathetic nervous system appears to be important. Angiotensin II receptor blocker drugs (ARBs) have provided a useful class of anti-hypertensive drugs. Eprosartan is a relatively new ARB which is chemically distinct (non-biphenyl, non-tetrazole) from all other ARBs (biphenyl tetrazoles). An analysis has been made on available experimental and clinical data on eprosartan which not only is an effective and well tolerated antihypertensive agent, but also lowers the activities of the renin-angiotensin system and sympathetic nervous system. Experimental and pharmacokinetic studies on eprosartan have shown differences with the other ARBs. The distinct properties of this non-biphenyl, non-tetrazole ARB might be relevant in the effort to reduce cardiovascular risk, also beyond its blood pressure lowering capacity.

  Keywords: Eprosartan, hypertension, sympathetic nervous system, renin angiotensin system
  Affiliation: Department of Nephrology, room F03.220, University Medical Center, Pobox 85500, 3508 GA Utrecht,The Netherlands.
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers


  Copyright © 1994 - 2015   Bentham Science Publishers